专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

WO1989010739A1 HYDROXYALKYL CYCLODEXTRIN-ANTIFUNGAL POLYENE ANTIBIOTICS COMPLEXES 审中-公开
标题翻译：羟克霉素环糊精 - 抗真菌多聚体抗生素复合物
公开(公告)号：WO1989010739A1
公开(公告)日：1989-11-16
申请号：PCT/US1989001912
申请日：1989-05-05
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , ANAISSIE, Elias, J. , PITHA, Joseph , BODEY, Gerald, P.
IPC分类号： A61K09/18
CPC分类号： B82Y5/00 , A61K31/7048 , A61K47/6951
摘要： The present invention involves a composition of matter comprising amphotericin B and hydroxyalkyl-gamma-cyclodextrin. The hydroxyalkyl-gamma-cyclodextrin is preferably hydroxypropyl-gamma-cyclodextrin, most preferably 2-hydroxypropyl-gamma-cyclodextrin. The cyclodextrin utilized in the practice of the present invention comprises rings of eight glucose units bound in 1-4 glucosidic linkages, each glucose unit having a hydroxyalkyl radical in ether linkage. The hydroxyalkyl radical is bound in ether linkage to carbon-5 of the glucose unit. The composition of matter of the present invention preferably comprises a cyclodextrin ring of eight glucose units bound in 1-4 glucosidic linkages, substantially each glucose unit having a 2-hydroxypropyl radical in ether linkage. The present invention also involves a method for the treatment of an animal with fungal infection. This method comprises administering to the animal a fungicidally effective amount of a composition of matter as described above comprising amphotericin B and hydroxyalkyl-gamma-cyclodextrin. The administration is preferably parenteral, particularly for disseminated fungal infection, but could be internal or topical, depending upon the particular site of fungal infection and desires of the treating physician. The disseminated fungal infection most preferably treated is a yeast infection such as a Candida albicans, Candida tropicalis, Candida parapsiloses or Torulopsis glabrata infection. The fungicidally effective amount useful for treatment of disseminated fungal infection contains between about 0.4 mg amphotericin B per kg body weight and about 4.0 mg amphotericin B per kg body weight.
摘要翻译：本发明涉及包含两性霉素B和羟烷基-γ-环糊精的物质组合物。羟烷基-γ-环糊精优选为羟丙基-γ-环糊精，最优选为2-羟丙基-γ-环糊精。在本发明的实践中使用的环糊精包含以1-4个糖苷键连接的8个葡萄糖单元的环，每个葡萄糖单元具有醚键中的羟烷基。羟烷基与醚键连接成葡萄糖单元的碳-5。本发明的物质组合物优选包含以1-4个糖苷键连接的8个葡萄糖单元的环糊精环，基本上每个葡萄糖单元具有醚键中的2-羟丙基。本发明还涉及一种用于治疗具有真菌感染的动物的方法。该方法包括向动物施用杀真菌有效量的包含两性霉素B和羟烷基-γ-环糊精的如上所述的物质组合物。给药优选为肠胃外，特别是对于播散性真菌感染，但可以是内部或局部，这取决于治疗医师的真菌感染和欲望的特定部位。最优选处理的播散性真菌感染是酵母感染，例如白色念珠菌，热带假丝酵母，副伤寒假丝酵母或光滑罗非鱼感染。用于治疗播散性真菌感染的杀真菌有效量含有约0.4mg两性霉素B / kg体重和约4.0mg两性霉素B / kg体重。

92. 发明申请

WO1989010722A1 HEAD POSITIONING SYSTEM FOR ACCURATE CRANIAL ALIGNMENT AND DIMENSION IN MAGNETIC RESONANCE 审中-公开
标题翻译：用于精确对称和尺寸在磁共振中的头部定位系统
公开(公告)号：WO1989010722A1
公开(公告)日：1989-11-16
申请号：PCT/US1989001881
申请日：1989-05-03
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , CHAVARRIA, Lazaro , MORGAN, Tommie, J.
IPC分类号： A61B05/05
CPC分类号： A61B6/501 , A61B5/0555 , A61B5/4528 , G01R33/28
摘要： The present invention relates to a portable head positioning system for the establishment and measurement of variety of different head orientations for the purposes of magnetic resonance imaging. The present system comprises a head engagement assembly and a mouthpiece or orientation component which cooperate to enable reproducible imaging.

93. 发明申请

WO1988001280A1 GLYCOSAMINOGLYCAN DERIVATIVES AND THEIR USE AS INHIBITORS OF TUMOR INVASIVENESS OR METASTATIC PROFUSION 审中-公开
标题翻译：谷氨酰胺糖苷衍生物及其作为肿瘤侵袭或分子生物学抑制剂的用途
公开(公告)号：WO1988001280A1
公开(公告)日：1988-02-25
申请号：PCT/US1987002035
申请日：1987-08-18
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , NICOLSON, Garth, L. , IRIMURA, Tatsuro , NAKAJIMA, Motowo
IPC分类号： C08B37/10
CPC分类号： A61K31/715 , C08B37/0075
摘要： Method for impeding the formation of tumor metastasis or tumor invasiveness in a host. Such inhibition comprises administration to the host of a glycosaminoglycan derivative substantially devoid of anticoagulation activity and is an effective inhibitory of heparanase activity. Such a glycosaminoglycan derivative may be provided by purchase or synthesis as directed herein. Parenteral administration to a tumor-bearing host of the glycosaminoglycan derivative results in the exposure of host-borne tumor cells thereto. Such exposure to effective levels of the derivative results in the inhibition of tumor heparanase activity and a lessening of invasiveness and metastatic spread. Heparin, a glycosaminoglycan particularly effective as a heparanase inhibitor and an anti-clotting agent, is a preferred glycosaminoglycan for derivatization. Upon derivatization according to the present invention heparin may be converted into a glycosaminoglycan derivative substantially devoid of anticoagulant activity but yet being an effective inhibitor of heparanase activity. Mere reduction of heparin carboxyl groups results in the production of a glycosaminoglycan derivative inhibitory to heparanase activity but without substantially anticoagulant activity non-anticoagulating, heparanase-inhibiting glycosaminoglycan derivatives may also be prepared from heparin, for example, by: at least partial N-desulfation and then N-acetylation; or N-, O-desulfation followed by N-resulfation.
摘要翻译：阻止宿主中肿瘤转移或肿瘤浸润形成的方法。这种抑制包括向宿主施用基本上没有抗凝活性的糖胺聚糖衍生物，并且是对肝素酶活性的有效抑制。这样的糖胺聚糖衍生物可以通过如本文所述的购买或合成来提供。对葡萄糖胺聚糖衍生物的肿瘤宿主的肠胃外给药导致宿主携带的肿瘤细胞暴露于其中。这种暴露于有效水平的衍生物导致抑制肿瘤乙酰肝素酶活性和降低侵袭性和转移性扩散。肝素，作为乙酰肝素酶抑制剂和抗凝血剂特别有效的糖胺聚糖是用于衍生化的优选的糖胺聚糖。根据本发明的衍生化，肝素可以转化为基本上没有抗凝血活性但仍然是乙酰肝素酶活性的有效抑制剂的糖胺聚糖衍生物。肝素羧基的简单还原导致抑制乙酰肝素酶活性但不具有非抗凝血活性的糖胺聚糖衍生物的产生，也可由肝素制备乙酰肝素酶抑制糖胺聚糖衍生物，例如：至少部分N-脱硫然后进行N-乙酰化; 或N-，O-脱硫，随后进行N-硫酸化。

94. 发明申请

WO1986002352A1 GADOLINIUM CHELATES AS NMR CONTRAST AGENTS 审中-公开
标题翻译：作为核磁共振对比剂的蓖麻子
公开(公告)号：WO1986002352A1
公开(公告)日：1986-04-24
申请号：PCT/US1985002014
申请日：1985-10-17
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , SHERRY, A., Dean
IPC分类号： C07D255/02
CPC分类号： C07F9/6524 , A61K49/06 , A61K51/04 , A61K2123/00 , C07D255/02 , C07D257/02 , C07F9/6515 , Y10S436/806 , Y10T436/24
摘要： Chelates of gadolinium with 1, 4, 7-triazacyclononane-N, N', N''-triacetate; 1, 4, 7, 10-tetrazacyclododecane-N, N', N'', N'''-tetraacetate; and 1, 5, 9-triazacyclododecane-N, N', N''-triacetate are useful as NMR contrast agents.

95. 发明申请

WO1998012347A1 RH BLOOD GROUP ANTIGEN COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： RH血液组合物及其使用方法
公开(公告)号：WO1998012347A1
公开(公告)日：1998-03-26
申请号：PCT/US1997017110
申请日：1997-09-17
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , BAYLOR COLLEGE OF MEDICINE , RODKEY, L., Scott , YARED, Marwan, A. , MOISE, Kenneth, J., Jr.
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , BAYLOR COLLEGE OF MEDICINE
IPC分类号： C12Q01/00
CPC分类号： G01N33/80 , A61K38/00 , C07K14/705 , C07K16/34 , Y10S435/975 , Y10S436/824 , Y10T436/10
摘要： Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.
摘要翻译：公开了包含可溶性和结合形式的免疫活性血型抗原（包括哺乳动物Rh抗原）的新型蛋白质和肽组合物。在优选实施方案中，公开了用于分离和纯化血清学活性的人Rh抗原如D，c，C，E和e的方法。还公开了用于将免疫活性Rh抗原吸附到固体支持物上的方法。还公开了用于在临床和非临床样品中检测Rh抗体的诊断试剂盒，方法和装置。还提供了用于从溶液中分离，纯化和定量抗Rh抗体的装置，组合物和方法。

96. 发明申请

WO1998008500A1 HYPERTONIC ARGININE COMPOSITIONS AND METHODS 审中-公开
标题翻译： HYPERTONIC ARGININE组合物和方法
公开(公告)号：WO1998008500A1
公开(公告)日：1998-03-05
申请号：PCT/US1997016203
申请日：1997-08-26
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , DEWITT, Douglas , KRAMER, George, C. , POLI DE FIGUEIREDO, Luiz, F. , MATHRU, Mali , PROUGH, Donald, S.
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
IPC分类号： A61K31/195
CPC分类号： A61K31/195 , A61K31/198 , A61K33/00 , A61K33/14 , A61K2300/00
摘要： The present invention concerns hypertonic formulations that are useful to treat hemorrhage and trauma, and particularly trauma of the central nervous system, brain and spinal cord and circulatory shock. Also disclosed is a method of effectively treating or preventing the pulmonary or systemic hypertension that may occur with hemoglobin infusions. Such hypertonic formulations include L-arginine in various hypertonic aqueous formulations that may also include an oxygen carrier.
摘要翻译：本发明涉及可用于治疗出血和创伤，特别是中枢神经系统，脑和脊髓的创伤以及循环性休克的高渗制剂。还公开了有效治疗或预防血红蛋白输注可能发生的肺或全身性高血压的方法。这种高渗制剂包括各种高渗含水制剂中的L-精氨酸，其也可包括氧载体。

97. 发明申请

WO1998008108A1 AN ELECTRONIC AUTOROUTING NAVIGATION SYSTEM FOR VISUALLY IMPAIRED PERSONS 审中-公开
标题翻译：用于视觉受损人员的电子自动导航系统
公开(公告)号：WO1998008108A1
公开(公告)日：1998-02-26
申请号：PCT/US1997014525
申请日：1997-08-19
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , HANCOCK, Michael, B.
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
IPC分类号： G01S03/02
CPC分类号： G01C21/20 , G01S1/70
摘要： The present invention is an autorouting navigation system (100) for directing one or more visually impaired persons to a physical location. The present invention includes a portable autonavigation unit (100) that includes an input device (106) for selecting a target location corresponding to a physical location of a plurality of location beacons, a receiver (101) configured to receive signals from location beacons, a memory (103) storing information correlating the locations of the location beacons, and an output device (104) for communicating with the user. A microcontroller (105) or microprocessor under program control processes the signals received from the location beacons, analyzes those signals and correlation data, and determines a routing path from the user's present position to the target location. The microcontroller (105) may also provide an indication, such as an audible sound, to the user of whether or not the user is following the routing path to the target location.
摘要翻译：本发明是一种用于将一个或多个视障人员引导到物理位置的自动布线导航系统（100）。本发明包括便携式自动导航单元（100），其包括用于选择对应于多个位置信标的物理位置的目标位置的输入设备（106），被配置为从位置信标接收信号的接收机（101）存储器（103）存储与位置信标的位置相关的信息，以及用于与用户通信的输出设备（104）。在程序控制下的微控制器（105）或微处理器处理从位置信标接收到的信号，分析这些信号和相关数据，并且确定从用户的当前位置到目标位置的路由路径。微控制器（105）还可以向用户提供关于用户是否遵循到目标位置的路由路径的指示，例如可听见的声音。

98. 发明申请

WO1998004291A1 2-METHOXYESTRADIOL-INDUCED APOPTOSIS IN CANCER CELLS 审中-公开
标题翻译： 2-METHOXYESTRADIOL诱导的癌症细胞凋亡
公开(公告)号：WO1998004291A1
公开(公告)日：1998-02-05
申请号：PCT/US1997012998
申请日：1997-07-24
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , MUKHOPADHYAY, Tapas , ROTH, Jack, A.
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
IPC分类号： A61K48/00
CPC分类号： A61K48/00 , A61K38/1709 , A61K2300/00
摘要： The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-Methoxyestradiol (2-MeOE2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE2 facilitates induction of p53-mediated apoptosis.
摘要翻译：本发明详细描述了治疗癌症的方法。特别地，它涉及用甲氧基雌二醇处理后诱导癌细胞凋亡。在与细胞周期蛋白依赖性激酶抑制剂p21WAF1 / CIP1的积累相关的人类非小细胞肺癌细胞系中，2-甲氧基雌二醇（2-MeOE2）增加野生型p53水平。药物治疗后发生明显的凋亡细胞死亡。因此，2-MeOE2促进p53介导的细胞凋亡的诱导。

99. 发明申请

WO1997048694A1 COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF 审中-公开
标题翻译：用于提供药物活性制剂的化合物和方法及其用途
公开(公告)号：WO1997048694A1
公开(公告)日：1997-12-24
申请号：PCT/US1997010643
申请日：1997-06-20
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , MUNDY, Gregory , KERWIN, Sean , HURLEY, Laurence, H. , DeLUCA, Mark, R. , MOORE, Bob, M., III
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , MUNDY, Gregory
IPC分类号： C07D401/04
CPC分类号： C07D215/38 , A61K31/428 , A61K31/47 , C07D277/82
摘要： The present invention relates to pharmacologically active compounds which are capable of binding to nuclear hormone receptors and are useful for the stimulation of osteoblast proliferation and ultimately bone growth. This invention also relates to the use of such compounds for the treatment or prevention of diseases and/or disorders associated with nuclear hormone receptor families.
摘要翻译：本发明涉及能够结合核激素受体并且可用于刺激成骨细胞增殖和最终骨生长的药理活性化合物。本发明还涉及这些化合物用于治疗或预防与核激素受体家族相关的疾病和/或病症的用途。

100. 发明申请

WO1997034609A1 TREATMENT OF OSTEOPOROSIS AND METABOLIC BONE DISORDERS WITH NITRIC OXIDE SUBSTRATE AND/OR DONORS 审中-公开
标题翻译：用硝酸氧化物底物和/或配子处理骨质疏松症和代谢性骨质疏松症
公开(公告)号：WO1997034609A1
公开(公告)日：1997-09-25
申请号：PCT/US1997004311
申请日：1997-03-18
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , YALLAMPALLI, Chandrasekhar , WILAMAWANSA, Sunil, J.
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
IPC分类号： A61K31/66
CPC分类号： A61K45/06 , A61K31/198 , A61K31/21 , A61K31/295 , A61K31/34 , A61K31/5377 , A61K31/565 , A61K31/195 , A61K2300/00
摘要： Primary and secondary osteoporosis in a female or a male mammal in any age treated by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally; in further combination with one or more of an estrogen, a progestin, a bisphosphonate, an anabolic steroid, testosterone, a flavinid, vitamin D analogue or a calcitonin. Nitric oxide substrate or donor also can be combined with one or more of the other medication acting on bone, such as bisphosphonate, calcitonin, fluoride, androgen, vitamin D analogue, and other novel therapeutic agents. Either nitric oxide donor or substrate by itself or in combination with other medications as described above can be used in both males and females, for prevention and treatment of osteopenia or osteoporosis, and other metabolic bone disorders.
摘要翻译：通过向其施用一氧化氮合酶底物，一氧化氮供体或二者任选地处理的任何年龄的雌性或雄性哺乳动物中的原发性和继发性骨质疏松症; 与雌激素，孕激素，双膦酸盐，合成代谢类固醇，睾酮，黄素，维生素D类似物或降钙素中的一种或多种的进一步组合。一氧化氮底物或供体也可与一种或多种其它作用于骨的药物组合，例如双膦酸盐，降钙素，氟化物，雄激素，维生素D类似物和其它新型治疗剂。本发明的一氧化氮供体或底物或与上述其它药物组合可用于男性和女性，用于预防和治疗骨质减少症或骨质疏松症以及其它代谢性骨骼疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式